Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)—report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group

BACKGROUND: The WHO recommended 1200mg/day of fluconazole (FCZ) in the induction phase of cryptococcal meningitis (CM) in HIV prior to 2018 in regions where amphotericin-B (AMB) was unavailable. A 2-stage AMB-controlled, dose-escalation study to determine the maximum tolerated dose and the safety/ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Lalloo, Umesh G., Komarow, Lauren, Aberg, Judith A., Clifford, David B., Hogg, Evelyn, McKhann, Ashley, Bukuru, Aggrey, Lagat, David, Pillay, Sandy, Mave, Vidya, Supparatpinyo, Khuanchai, Samaneka, Wadzanai, Langat, Deborah, Ticona, Eduardo, Badal-Faesen, Sharlaa, Larsen, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925064/
https://www.ncbi.nlm.nih.gov/pubmed/36780493
http://dx.doi.org/10.1371/journal.pone.0281580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925064/
https://www.ncbi.nlm.nih.gov/pubmed/36780493
http://dx.doi.org/10.1371/journal.pone.0281580

Ejemplares similares